Weight Loss Fails High-Risk Diabetes Subgroup
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- German Center for Diabetes Research (DZD) scientists found that individuals in type 2 diabetes risk cluster 5 still showed rising blood glucose, declining insulin secretion, and persistently high diabetes risk despite losing ~8% of body weight and sustaining that loss over a 9-year follow-up.
- Professor Norbert Stefan, the lead author, said the team was 'very surprised' that cluster 5 participants continued to deteriorate metabolically even after such large and sustained weight loss.
- The analysis drew on the Tübingen Lifestyle Intervention Program (TULIP), in which high-risk participants completed a two-year lifestyle program and were then tracked for approximately nine years.
- Insulin resistance linked to severe fatty liver disease appeared to be the main driver of cluster 5's worsening metabolic health, with liver fat also impairing pancreatic beta-cell insulin release.
- DZD researchers previously partitioned pre-diabetes into six distinct risk clusters, of which clusters 3 and 5 carry the highest likelihood of progressing to overt type 2 diabetes.
- The findings, published in the journal Diabetes, support earlier evidence that cluster 5 is dominated by fatty-liver-driven insulin resistance, putting members at elevated risk for both type 2 diabetes and cardiovascular disease.
- The authors argue that diabetes prevention may need to become more personalized, with cluster 5 patients potentially requiring more intensive or targeted therapies rather than standard lifestyle advice alone.
Why it matters: The study identifies a biological subgroup — cluster 5 patients with fatty-liver-driven insulin resistance — for whom standard 'lose weight and exercise' prevention advice fails even at 8% body-weight loss and 9 years of follow-up. Roughly speaking, this means one-time lifestyle prescriptions may be insufficient for the highest-risk pre-diabetes patients, and future guidelines may need to route them toward liver-targeted or pharmacological interventions instead.
